ERBB2 and neoplasm: 52Mn-labelled trastuzumab showed high in vivo stability and efficient targeting ability for HER2 overexpressing tumours in animal models, mice bearing BT474 tumour, acting as efficient PET radiotracer capable of tracking tumour growth and evaluating therapeutic outcomes with time.